Literature DB >> 26163324

Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.

Noah K Yuen1, Chin-Shang Li2, Arta M Monjazeb3, Dariusz Borys4, Richard J Bold1, Robert J Canter5.   

Abstract

BACKGROUND: Radiation therapy (RT) is a standard component in the multimodality management of localized soft tissue sarcoma (STS). Increasing studies are focusing on biological modifiers that may influence the host's response to RT, including immunologic mechanisms known to change with the aging process. We hypothesized that the effects of RT would be influenced by age, contributing to differences in treatment outcome.
METHODS: Using Surveillance, Epidemiology, and End Results (1990-2011), we identified 30,898 adult patients (>18 y) with nonmetastatic STS undergoing initial surgery. We compared patient demographics, tumor characteristics, and treatments by age. Multivariable analyses were used to analyze overall survival (OS) and disease-specific survival (DSS). Hazard ratios (HRs) were calculated based on multivariable Cox proportional hazards models.
RESULTS: Mean age at diagnosis was 56.6 ± 16.8 y, and 33.6% of patients were ≥65 y. Of the total, 52.1% of patients were male and 67% were white; 59.9% of patients underwent surgery alone, 33.3% received adjuvant RT, and 6.8% neoadjuvant RT. On multivariable analysis, age, sex, year of diagnosis, histology, grade, size, marital status, and RT predicted OS, whereas age, year of diagnosis, ethnicity, histology, site, grade, RT, size, and marital status predicted DSS. In all patients, RT was associated with improved OS and DSS compared to surgery alone (median OS 136 ± 13 mo with RT versus 118 ± 9 mo without RT and 5-y OS 63.2 ± 1.4% with RT versus 60.5 ± 1.2% without, P < 0.01). Patients ≥65 y derived greater improvements in OS and DSS compared with patients <65 y. These benefits were most notable after neoadjuvant RT with patients ≥65 y having significantly better OS (HR = 0.63; 95% confidence interval = 0.53-0.75), whereas patients <65 y did not (HR = 0.96; 95% confidence interval = 0.83-1.10). In addition, interaction testing demonstrated a significant modifier effect between RT and age (P < 0.05).
CONCLUSIONS: RT is associated with improved survival in patients with STS undergoing surgical treatment, but improvements in oncologic outcome with RT were greatest among older patients. Further studies into the mechanism of these age-related effects are needed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age; Radiotherapy; Soft tissue sarcoma; Surgery

Mesh:

Year:  2015        PMID: 26163324      PMCID: PMC4789295          DOI: 10.1016/j.jss.2015.06.020

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  40 in total

Review 1.  Factors influencing inclusion of patients with malignancies in clinical trials.

Authors:  Caroline Tournoux; Sandrine Katsahian; Sylvie Chevret; Vincent Levy
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

2.  Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.

Authors:  Joal D Beane; James C Yang; Donald White; Seth M Steinberg; Steven A Rosenberg; Udo Rudloff
Journal:  Ann Surg Oncol       Date:  2014-04-23       Impact factor: 5.344

3.  Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas.

Authors:  Robert J Canter; Shannon Beal; Dariusz Borys; Steve R Martinez; Richard J Bold; Anthony S Robbins
Journal:  J Am Coll Surg       Date:  2009-12-04       Impact factor: 6.113

4.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Authors:  P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

5.  Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival.

Authors:  Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

Review 6.  Regulatory T cells and the immune aging process: a mini-review.

Authors:  Ann Jagger; Yasuhiro Shimojima; Jorg J Goronzy; Cornelia M Weyand
Journal:  Gerontology       Date:  2013-11-28       Impact factor: 5.140

7.  Radiotherapy of human sarcoma promotes an intratumoral immune effector signature.

Authors:  Anu Sharma; Beata Bode; Gabriela Studer; Holger Moch; Michal Okoniewski; Alexander Knuth; Lotta von Boehmer; Maries van den Broek
Journal:  Clin Cancer Res       Date:  2013-07-16       Impact factor: 12.531

8.  Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis.

Authors:  Matthew Koshy; Shayna E Rich; Majid M Mohiuddin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-11       Impact factor: 7.038

9.  Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment.

Authors:  Sandra Demaria; Karsten A Pilones; Silvia C Formenti; Michael L Dustin
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

10.  Radiotherapy effects on anti-tumor immunity: implications for cancer treatment.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2013-05-22       Impact factor: 6.244

View more
  1 in total

1.  Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER.

Authors:  Stephen J Ramey; Raphael Yechieli; Wei Zhao; Joyson Kodiyan; David Asher; Felix M Chinea; Vivek Patel; Isildinha M Reis; Lily Wang; Breelyn A Wilky; Ty Subhawong; Jonathan C Trent
Journal:  Cancer Med       Date:  2018-07-20       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.